A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum

被引:127
作者
Mikolajczyk, SD [1 ]
Grauer, LS [1 ]
Millar, LS [1 ]
Hill, TM [1 ]
Kumar, A [1 ]
Rittenhouse, HG [1 ]
Wolfert, RL [1 ]
Saedi, MS [1 ]
机构
[1] HYBRITECH INC,SAN DIEGO,CA
关键词
D O I
10.1016/S0090-4295(97)00449-4
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives, Prostate-specific antigen (PSA) is a widely used serum marker for human prostate cancer (PCa). The majority of PSA in serum is present as a complex with alpha-1-antichymotrypsin (ACT). In recent years, the ratio of free (uncomplexed) to total PSA has shown improved discrimination of PCa from benign prostatic hyperplasia. This study examines the nature of the free PSA form detected in PCa serum and shows that some of the uncomplexed PSA is an inactive precursor of PSA (pPSA). Methods. Western blot analysis was used to detect clipped, fragment forms of PSA in sera and seminal fluid. Hydrophobic interaction chromatography-high performance liquid chromatography (HIC-HPLC) was used to identify forms of PSA present in the free PSA population. Pooled sera was passed over a PSA immunoaffinity column, and the eluted PSA components were further resolved by HIC-HPLC. Results. Western blot analysis of whole sera showed complexed PSA and the intact, approximately 34 kilodalton free PSA. Only negligible levels of clipped or degraded forms of PSA, as found in seminal fluid, were detected. Column fractions measured for uncomplexed PSA using the Tandem-MP free PSA assay showed that about 25% of the free PSA eluted as pPSA beginning at the [-4]amino acid. Studies with purified recombinant [-4]pPSA showed that this proenzyme form is inactive and does not complex with ACT. Conclusions. These results suggest that the uncomplexed PSA in PCa serum is primarily unclipped PSA that contains a significant fraction of pPSA. (C) 1997, Elsevier Science Inc. All rights reserved.
引用
收藏
页码:710 / 714
页数:5
相关论文
共 22 条
  • [1] SCREENING FOR PROSTATIC-CARCINOMA WITH PROSTATE SPECIFIC ANTIGEN
    BRAWER, MK
    CHETNER, MP
    BEATIE, J
    BUCHNER, DM
    VESSELLA, RL
    LANGE, PH
    [J]. JOURNAL OF UROLOGY, 1992, 147 (03) : 841 - 845
  • [2] STRUCTURAL COMPARISON OF PROSTATE-SPECIFIC ANTIGEN AND HUMAN GLANDULAR KALLIKREIN USING MOLECULAR MODELING
    BRIDON, DP
    DOWELL, BL
    [J]. UROLOGY, 1995, 45 (05) : 801 - 806
  • [3] MEASUREMENT OF PROSTATE-SPECIFIC ANTIGEN IN SERUM AS A SCREENING-TEST FOR PROSTATE-CANCER
    CATALONA, WJ
    SMITH, DS
    RATLIFF, TL
    DODDS, KM
    COPLEN, DE
    YUAN, JJJ
    PETROS, JA
    ANDRIOLE, GL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (17) : 1156 - 1161
  • [4] CATALONA WJ, 1996, PROSTATE S, V7, P64
  • [5] Chen ZX, 1997, J UROLOGY, V157, P2166, DOI 10.1016/S0022-5347(01)64704-9
  • [6] SERUM PROSTATE-SPECIFIC ANTIGEN COMPLEXED TO ALPHA-1-ANTICHYMOTRYPSIN AS AN INDICATOR OF PROSTATE-CANCER
    CHRISTENSSON, A
    BJORK, T
    NILSSON, O
    DAHLEN, U
    MATIKAINEN, MT
    COCKETT, ATK
    ABRAHAMSSON, PA
    LILJA, H
    [J]. JOURNAL OF UROLOGY, 1993, 150 (01) : 100 - 105
  • [7] ENZYMATIC-ACTIVITY OF PROSTATE-SPECIFIC ANTIGEN AND ITS REACTIONS WITH EXTRACELLULAR SERINE PROTEINASE-INHIBITORS
    CHRISTENSSON, A
    LAURELL, CB
    LILJA, H
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1990, 194 (03): : 755 - 763
  • [8] Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: A novel prostate cancer marker
    Darson, MF
    Pacelli, A
    Roche, P
    Rittenhouse, HG
    Wolfert, RL
    Young, CYF
    Klee, GG
    Tindall, DJ
    Bostwick, DG
    [J]. UROLOGY, 1997, 49 (06) : 857 - 862
  • [9] Kumar A, 1996, CANCER RES, V56, P5397
  • [10] Kumar A, 1997, CANCER RES, V57, P3111